Table 6.
Reclassification of 55 CVID patients smB+/-, separated according to experience of complications
|
Model with EUROclass |
Model with EUROclass and CD8+ HLA-DR+ |
Total |
|
|---|---|---|---|
| Predicted probabilities (%) | < 50% | ≥ 50% | |
|
Patients who experienced CVID complications |
|
|
|
| < 50% |
9 |
 |
19 |
| ≥ 50% |
1 |
5 |
6 |
| Total |
10 |
15 |
25 |
|
Patients who didn’t experience CVID complications |
|
|
|
| < 50% |
22 |
5 |
27 |
| ≥ 50% |
2 |
1 |
3 |
| Total | 24 | 6 | 30 |
ALTADIH Cohort, 2007-2010.
The agreements between the two models for classifying the patients are depicted in gray. Adding CD8 + HLA-DR + to EUROclass model leads to better determine CVID complications for 10 patients who experienced CVID complications (upward movement in category for patients who experienced CVID complications) and to better determine the absence of CVID complications for 2 patients who did not experience CVID complications (downward movement in category for patients who did not experience CVID complications). In parallel, it leads to worsened classification for 1 patient who experienced CVID complications (downward movement in category for patients who did experience CVID complications) and 5 patients who did not experience CVID complications (upward movement in category for patients who did not experience CVID complications).
The positive net reclassification improvement (0.26) revealed that CD8+ HLA-DR + offers improved prediction of CVID complications.